Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study
Francesco Patti(University of Catania), Diego Centonze(University of Rome Tor Vergata), María Trojano(University of Bari Aldo Moro), Claudio Gasperini(Nini Hospital), Maria Pia Amato(University of Florence), Orietta Picconi(Istituto Superiore di Sanità), Stefano Bastianello(Sapienza University of Rome), M. R. Tola(Vita-Salute San Raffaele University), Sabina Cilia, Salvatore Cottone
Cited by 50
Related Papers
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
|The Lancet Neurology|2017|8k
Multiple Sclerosis Severity Score
|Neurology|2005|959
MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines
|The Lancet Neurology|2016|863
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
|Multiple Sclerosis Journal|2018|706
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis
|The Lancet Neurology|2021|646